AVAC briefing on PrEPVacc: An in-depth look at the trial, and what’s next
11 January 2024
During this webinar hosted by AVAC, the PrEPVacc team and AVAC reviewed the status of the PrEPVacc trial following the recent discontinuation of vaccinations due to the independent data monitoring committee’s conclusion that the vaccines were having no effect in preventing HIV infection. The webinar covered key aspects of PrEPVacc, including its innovative study design, implementation, integrated social science, and data analysis plans.
Speakers engaged in conversation about what has been learned so far from PrEPVacc, what we can still learn, and what this may mean for the HIV prevention field.
PrEPVacc Trial Design: Sheena McCormack, PrEPVacc Project Lead, MRC Clinical Trials Unit, University College London, UK
Trial Implementation and Baseline Data: Eugene Ruzagira, PrEPVacc Trial Director, MRC/UVRI & LSHTM Uganda Research Unit
Integrated Social Science: Rachel Kawuma, PrEPVacc Social Scientist, MRC/UVRI & LSHTM Uganda Research Unit
Analysis Plan: Sheila Kansiime, PrEPVacc Statistician, MRC/UVRI & LSHTM Uganda Research Unit
Links to resources:
PrEPVacc warmly thanks AVAC for its support throughout the study and for hosting this webinar.